Sarah I Sheikh
Overview
Explore the profile of Sarah I Sheikh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1286
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dauvilliers Y, Mignot E, Del Rio Villegas R, Du Y, Hanson E, Inoue Y, et al.
N Engl J Med
. 2023 Jul;
389(4):309-321.
PMID: 37494485
Background: Narcolepsy type 1 is caused by severe loss or lack of brain orexin neuropeptides. Methods: We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor...
2.
Ebrahimi-Fakhari D, Teinert J, Behne R, Wimmer M, DAmore A, Eberhardt K, et al.
Brain
. 2020 Sep;
143(10):2929-2944.
PMID: 32979048
Bi-allelic loss-of-function variants in genes that encode subunits of the adaptor protein complex 4 (AP-4) lead to prototypical yet poorly understood forms of childhood-onset and complex hereditary spastic paraplegia: SPG47...
3.
Sheikh S, Guerciolini R
N Engl J Med
. 2019 Sep;
381(12):1181.
PMID: 31532969
No abstract available.
4.
Cadavid D, Mellion M, Hupperts R, Edwards K, Calabresi P, Drulovic J, et al.
Lancet Neurol
. 2019 Jul;
18(9):845-856.
PMID: 31285147
Background: Opicinumab is a human monoclonal antibody against LINGO-1, an inhibitor of oligodendrocyte differentiation and axonal regeneration. Previous findings suggested that opicinumab treatment might enhance remyelination in patients with CNS...
5.
Saida T, Yamamura T, Kondo T, Yun J, Yang M, Li J, et al.
BMC Neurol
. 2019 Jan;
19(1):5.
PMID: 30616596
Background: Delayed-release dimethyl fumarate (DMF) has demonstrated efficacy and a favorable benefit-risk profile in phase 2 and 3 studies that enrolled predominantly white patients with relapsing-remitting multiple sclerosis (RRMS). In...
6.
Kita M, Fox R, Gold R, Giovannoni G, Phillips J, Sarda S, et al.
Clin Ther
. 2018 Mar;
40(5):812.
PMID: 29523369
No abstract available.
7.
Sheikh S
Neurodegener Dis Manag
. 2018 Feb;
8(1):13-15.
PMID: 29384036
Sarah Isabel Sheikh speaks to Laura Dormer, Commissioning Editor: Sarah I Sheikh, MD, MSc, MRCP, is a Senior Medical Director in Late Stage Clinical Development at Biogen. Her current focus...
8.
von Hehn C, Howard J, Liu S, Meka V, Pultz J, Mehta D, et al.
Neurol Neuroimmunol Neuroinflamm
. 2017 Nov;
5(1):e409.
PMID: 29159204
Objectives: To investigate the immune response to vaccinations in patients with relapsing forms of MS treated with delayed-release dimethyl fumarate (DMF) vs nonpegylated interferon (IFN). Methods: In this open-label, multicenter...
9.
Zhu B, Nestorov I, Zhao G, Meka V, Leahy M, Kam J, et al.
Clin Pharmacol Drug Dev
. 2017 Aug;
6(6):604-613.
PMID: 28783872
Delayed-release dimethyl fumarate (DMF) is an oral therapy for relapsing multiple sclerosis with anti-inflammatory and neuroprotective properties. This 2-period crossover study was conducted to evaluate the potential for drug-drug interaction...
10.
Calkwood J, Vollmer T, Fox R, Zhang R, Novas M, Sheikh S, et al.
Int J MS Care
. 2016 Jun;
18(3):138-46.
PMID: 27252601
Background: Delayed-release dimethyl fumarate (DMF; also known as gastroresistant DMF) is indicated for relapsing multiple sclerosis (MS). The objective of this study was to explore the safety and tolerability of...